Mark Dayan

With resident doctors beginning strike action again today, we have updated our analysis of doctors' pay. #doctorsstrike Read our explainer here: buff.ly/sFnmx8x The chart below shows real-terms changes to pay for consultants and resident doctors since 1990. 👇

We've updated our explainer on doctors' pay in England 👨‍⚕️ It includes this analysis of real-terms changes to resident doctors' pay since 2010/11. We also explore longer-term trends in doctors' pay, and how it compares with the wider economy. Read here: buff.ly/sFnmx8x

Can this government's plan repeat the New Labour NHS miracle? The same 2000s-era schemes are in there. The promises are actually bigger. The problem is that money, and the wider state of the UK, will be much more of an obstacle. My article in @TheHouseMag politicshome.com/news/article/w…

🆕 The #NHS 10 Year Plan - Satisfaction not guaranteed. @markgdayan explores the current context for the government's health plan compared with what happened during the last Labour government. Read via @politicshome @TheHouseMag 👇 politicshome.com/news/article/w…

Trump has opened whole new fronts in the long US struggle to make us pay more for medicines - just as the UK's cost control system is decaying into annual arguments. @sallygainsbury & I explain, and ask what the NHS should really want from its drugs bill nuffieldtrust.org.uk/news-item/trum…

🆕 Following recent press speculation that the UK may soon agree to pay more for drugs used within the #NHS as part of a trade deal with the USA, we asked experts @markgdayan and @sallygainsbury to explain the situation. 💊 nuffieldtrust.org.uk/news-item/trum…

With the #CovidInquiry now focusing on #socialcare, and with the sector in desperate need of reform, Nuffield Trust & @CPEC_LSE have published international case studies on how other countries managed social care challenges during the pandemic. Read here: nuffieldtrust.org.uk/research/build…

Assisted dying is now likely to pass into English & Welsh law. A tough task implementing it is ahead, including facing the gaps in end of life care highlighted by MPs. We must learn from other countries, who show how different paths can be👇 @SarahScobie2 nuffieldtrust.org.uk/news-item/now-…

Scotland's "Renewal Framework" for health & care will be an interesting contrast with the English 10 Year Plan: firmly sticking with joint local planning instead of autonomy and incentives. Comes with a plan for non-NHS prevention, which England's will not gov.scot/news/creating-…

Spending on newer medicines has already been soaring and we struggle to sustain the mechanism to claw it back from pharma firms. There's no wriggle room. If the NHS has to pay £100ms, £bns more for the same products, it will need to cut aspirations on waiting times, digitisation

How can the #NHS eat up tens of billions and not far off 3% real terms increases, and still struggle? For context see @sallygainsbury briefing on what has happened the last two years - exactly this. Must think carefully about the costs and demands on it nuffieldtrust.org.uk/resource/down-…

The #NHS settlement from the #spendingreview may look generous, but it soon melts away in the context of existing commitments. Social care is also unlikely to see the transformation we were promised. @sallygainsbury response 👇 nuffieldtrust.org.uk/news-item/nuff…

Ahead of the SR next week, my long read today looks at where the £22.6bn extra cash chancellor Reeves added to health spending in England for this year has gone. A thread >>

The UK has decisions to make on AI regulation for medical technology. Going our own way may help us get new technology, but would leave some uses unregulated and cement EU barriers, @markgdayan @NuffieldTrust bmj.com/content/389/bm…

🆕 blog on #AI in health care from @markgdayan and @cglobont in @bmj_latest. The UK has decisions to make on AI regulation for medical devices - going our own way may help us get new tech, but would leave some uses unregulated and cement EU barriers. buff.ly/qGi5HgR

Hard to be sure if Trump can really bully pharma industry into matching UK and US prices. But it could not come at a worse time for the NHS, which will be cash-strapped for years and has just agreed to review the accidentally generous VPAG cashback arrangement on branded drugs!